Virus News and Research

Latest Virus News and Research

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

As pandemic surged, contact tracing struggled; Biden looks to boost it

Contact tracing, a critical part of efforts to slow the spread of the coronavirus, has fallen behind in recent months as covid-19 cases have soared. President Joe Biden had pledged to change that.

10 Feb 2021

Farmworker camps to urban tent cities: Tailoring vaccine info to where it’s most needed

Kim Wagenaar has been preparing to bring covid-19 vaccines to western North Carolina for months.

10 Feb 2021

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Researchers highlight the potential causes of some COVID-19 symptoms. Early in the pandemic, the hallmark symptoms of COVID-19 include cough, fever, and shortness of breath. As the pandemic has evolved, more symptoms have emerged, such as loss of smell and taste, headache, intestinal issues, and abdominal pains.

10 Feb 2021

Study investigates how people are receiving and interpreting information about coronavirus

Swedish Television (SVT) remains the most common and trustworthy news source about the coronavirus for Swedes. Healthcare professionals are the professional group that Swedes have the most confidence in.

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Researchers at Northwestern University have noted high rates of asymptomatic and mild infection in a large community-based cohort and low levels of anti-SARS-CoV-2 immunoglobulin G antibody (IgG) in the general population of previously exposed people.

10 Feb 2021

Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection

Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.

10 Feb 2021

Study: SARS-CoV-2-related coronaviruses are circulating in Southeast Asian animals

While the World Health Organization (WHO) continues its mission to Wuhan investigating the origin and early transmission of SARS-CoV-2, a new study led by scientists from Duke-NUS Medical School, Singapore, and Chulalongkorn University, Thailand, shows that SARS-CoV-2-related coronaviruses (SC2r-CoVs) are circulating in animals as far away as Thailand.

10 Feb 2021

Pediatric trial results show rabies treatment is safe and effective in children

A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under.

10 Feb 2021

Scientists are exploring new possibilities to make more effective COVID-19 vaccines

Advances in the fields of biomaterials and nanotechnology could lead to big breakthroughs in the fight against dangerous viruses like the novel coronavirus that causes COVID-19.

10 Feb 2021

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.

10 Feb 2021

Researchers detect traces of COVID-19 virus in sewage flowing from campus buildings

Although it is still challenging to prevent the transmission of COVID-19, researchers at the University of Miami are using all the strategies they can to fend off the spread.

10 Feb 2021

UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

Monoclonal antibodies are showing promise for improving outcomes for COVID-19 patients, but when a hospital is already beyond capacity, administering them can be a challenge.

10 Feb 2021

Scientists urge health agencies to invest in COVID-19 vaccine development to prevent next pandemic

As new COVID-19 variants begin to throw vaccine efficacy in question, two leading scientists are calling for health agencies to invest in the development of vaccines that would be broadly effective against many different variants and strains of potential pandemic viruses.

10 Feb 2021

Relaxed control measures are driving wintertime outbreaks of COVID-19

Wintertime outbreaks of COVID-19 have been largely driven by whether people adhere to control measures such as mask wearing and social distancing, according to a study published Feb. 8 in Nature Communications by Princeton University researchers.

10 Feb 2021

Fred Hutch researchers predict a 4th wave of SARS-CoV-2

Recently, researchers from France and the USA analyzed the complexities of vaccine implementation during the 3rd wave of SARS-CoV-2 infections and potentially future waves, using a mathematical model calibrated to data from King County, Washington.

9 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

SARS-CoV-2 B.1.1.7 may soon become the dominant variant in US

A team of scientists from the United States has recently explored the prevalence and transmission dynamics of the B.1.1.7 variant (UK variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States. The study reveals that because of 35-45% increased transmissibility, B.1.1.7 may soon become the US's dominant variant. The study is currently available on the medRxiv* preprint server.

9 Feb 2021

Virus News and Research

Latest Virus News and Research

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

As pandemic surged, contact tracing struggled; Biden looks to boost it

Farmworker camps to urban tent cities: Tailoring vaccine info to where it’s most needed

Could a SARS-CoV-2 accessory protein be responsible for certain COVID-19 symptoms?

Study investigates how people are receiving and interpreting information about coronavirus

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection

Study: SARS-CoV-2-related coronaviruses are circulating in Southeast Asian animals

Pediatric trial results show rabies treatment is safe and effective in children

Scientists are exploring new possibilities to make more effective COVID-19 vaccines

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Researchers detect traces of COVID-19 virus in sewage flowing from campus buildings

UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

Scientists urge health agencies to invest in COVID-19 vaccine development to prevent next pandemic

Relaxed control measures are driving wintertime outbreaks of COVID-19

Fred Hutch researchers predict a 4th wave of SARS-CoV-2

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

SARS-CoV-2 B.1.1.7 may soon become the dominant variant in US

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Virus News and Research

Latest Virus News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in